FDA declares Wegovy® and Ozempic® shortage is over

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has determined the shortage of Wegovy® and Ozempic® is resolved. The FDA’s assessment confirms the U.S. supply of these prescription-only GLP-1 medicines now meets or exceeds both current and projected U.S. demand.

All doses of the only real FDA-approved semaglutide medicines are being continuously shipped, meeting or exceeding expected U.S. demand.

FDA’s decision means that making or selling a knockoff compounded drug that is essentially a copy of Ozempic or Wegovy is illegal, under compounding laws, with rare exceptions.

LabNews Media LLC

LabNews: Biotech. Digital Health. Life Sciences. Pugnalom: Environmental News. Nature Conservation. Climate Change. augenauf.blog: Wir beobachten Missstände

Vollständige Bio ansehen